GSK plc's stock rose by 3.63% and reached a 52-week high, reflecting positive market sentiment amid broader market gains with the Nasdaq-100 up 0.31% and the S&P 500 up 0.11%.
The increase in GSK's stock price is attributed to the recent approval of Exdensur (depemokimab) by Japan's Ministry of Health for treating severe asthma, marking a significant regulatory milestone for the company. This approval, supported by data from the SWIFT and ANCHOR phase III trials, enhances GSK's market position and potential demand for the drug, which is also under review in other countries.
This approval not only strengthens GSK's portfolio in the respiratory sector but also reflects the company's ongoing commitment to innovation in drug development. The positive market reaction indicates investor confidence in GSK's growth prospects following this significant regulatory achievement.
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 50.800
Low
20.15
Averages
38.72
High
55.60
Current: 50.800
Low
20.15
Averages
38.72
High
55.60
Citi
Graham Parry
Neutral
initiated
£1,900
2026-01-27
New
Reason
Citi
Graham Parry
Price Target
£1,900
AI Analysis
2026-01-27
New
initiated
Neutral
Reason
Citi analyst Graham Parry initiated coverage of GSK with a Neutral rating and 1,900 GBp price target. The firm sees mid-term growth challenges for GSK due to loss of exclusivities.
Clear Street
Buy
to
Hold
downgrade
$60 -> $58
2026-01-20
Reason
Clear Street
Price Target
$60 -> $58
2026-01-20
downgrade
Buy
to
Hold
Reason
Clear Street downgraded Rapt Therapeutics (RAPT) to Hold from Buy with a price target of $58, down from $60, after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash. Clear Street cites the deal terms for the downgrade.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GSK
Unlock Now
Piper Sandler
Overweight -> Neutral
downgrade
$95 -> $58
2026-01-20
Reason
Piper Sandler
Price Target
$95 -> $58
2026-01-20
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Rapt Therapeutics (RAPT) to Neutral from Overweight with a price target of $58, down from $95, after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash.
Guggenheim
Buy -> Neutral
downgrade
$58
2026-01-20
Reason
Guggenheim
Price Target
$58
2026-01-20
downgrade
Buy -> Neutral
Reason
Guggenheim downgraded Rapt Therapeutics (RAPT) to Neutral from Buy after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash.
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
